Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-SHCS: BG505 SOSIP.GT1.1 gp140 Vaccine in Adults Living With HIV
NCT07769983Phase 1Enrolling by invitation
- Sponsor
- University of Zurich
- Start
- Feb 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BG505 SOSIP GT1.1 gp140 in human immunodeficiency virus infection (HIV), sponsored by University of Zurich. Primary endpoints: Safety - reactogenicity at 7 days, Safety - IP related unsolicited adverse events at 28 days and 3 more. Started Feb 2025; status: enrolling by invitation.
02
Drugs
BG505 SOSIP GT1.1 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07769983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769983.